Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.

[1]  E. Fonseca,et al.  Molecular pathology of well-differentiated thyroid carcinomas , 2005, Virchows Archiv.

[2]  K. Pavelić,et al.  Aberration of FHIT Gene is Associated with Increased Tumor Proliferation and Decreased Apoptosis—Clinical Evidence in Lung and Head and Neck Carcinomas , 2001, Molecular Medicine.

[3]  J. Adolfsson,et al.  p53 mutations in urinary bladder cancer , 2001, British Journal of Cancer.

[4]  K. Huebner,et al.  Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53−/− mice , 2001, Oncogene.

[5]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[6]  K. L. La Perle,et al.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. , 2000, The American journal of pathology.

[7]  N. Eberhardt,et al.  FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance , 2000, Clinical endocrinology.

[8]  S. Lam,et al.  High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. , 2000, Cancer research.

[9]  K. Tanimoto,et al.  Abnormalities of the FHIT gene in human oral carcinogenesis , 2000, British Journal of Cancer.

[10]  Y. Pekarsky,et al.  FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. , 1999, Cancer research.

[11]  C. Croce,et al.  The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Minna,et al.  Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. , 1999, Cancer research.

[13]  S. Al-Sedairy,et al.  FHIT gene abnormalities in both benign and malignant thyroid tumours. , 1999, European journal of cancer.

[14]  Jong Y. Park,et al.  A high prevalence of p53 mutations in pre‐malignant oral erythroplakia , 1999, International journal of cancer.

[15]  L. D. Barnes,et al.  Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Wolfson,et al.  Diadenosine oligophosphates (Ap n A), a novel class of signalling molecules? , 1998, FEBS letters.

[17]  A. Arezzo,et al.  Mucoepidermoid carcinoma of the thyroid gland arising from a papillary epithelial neoplasm. , 1998, The American surgeon.

[18]  L. D. Barnes,et al.  Replacement of Fhit in cancer cells suppresses tumorigenicity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Eberhardt,et al.  Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. , 1997, The Journal of clinical endocrinology and metabolism.

[20]  T. Seyama,et al.  Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis , 1997, Oncogene.

[21]  P. Komminoth.  The RET proto-oncogene in medullary and papillary thyroid carcinoma , 1997, Virchows Archiv.

[22]  L. Cantley,et al.  Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. , 1997, Science.

[23]  G. Giaccone,et al.  FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. , 1997, Cancer research.

[24]  A. Marchetti,et al.  Association between cigarette smoking and FHIT gene alterations in lung cancer. , 1997, Cancer research.

[25]  S. Tamakuma,et al.  Expression of Wild-Type p53 Tumor Suppressor Gene and Its possible Involvement in the Apoptosis of Thyroid Tumors , 1997, Surgery Today.

[26]  S. Filetti,et al.  p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells , 1997, Oncogene.

[27]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[28]  C. Croce,et al.  FHIT gene alterations in head and neck squamous cell carcinomas. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  C. Croce,et al.  The FHIT gene at 3p14.2 is abnormal in breast carcinomas. , 1996, Cancer research.

[30]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[31]  M. Rugge,et al.  Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. , 1996, Cancer research.

[32]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[33]  Z. Sápi,et al.  Contribution of p53 Gene Alterations to Development of Metastatic Forms of Follicular Thyroid Carcinoma , 1995, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[34]  G. Viglietto,et al.  A mutated p53 gene alters thyroid cell differentiation. , 1995, Oncogene.

[35]  Q. Duh,et al.  Thyroid growth factors, signal transduction pathways, and oncogenes. , 1995, The Surgical clinics of North America.

[36]  E. Musulen,et al.  p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. , 1994, Journal of clinical pathology.

[37]  M. Zou,et al.  Molecular basis of thyroid cancer. , 1994, Endocrine reviews.

[38]  A. Knudson,et al.  Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Zou,et al.  p53 mutations in all stages of thyroid carcinomas. , 1993, The Journal of clinical endocrinology and metabolism.

[40]  S. Goodman,et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.

[41]  M. Pierotti,et al.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. , 1993, The Journal of clinical investigation.

[42]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression , 1992 .

[43]  T. Seyama,et al.  Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. , 1992, Cancer research.

[44]  R. Weinberg,et al.  Tumor suppressor genes. , 1991, Science.

[45]  J. Rosai,et al.  Anaplastic thyroid carcinoma. A study of 70 cases. , 1985, American journal of clinical pathology.

[46]  Tetsuro Kobayashi,et al.  MULTISTEP CARCINOGENESIS IN ANAPLASTIC THYROID CARCINOMA: A CASE REPORT , 2002, Pathology.

[47]  N. Eberhardt,et al.  FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. , 2000, Clinical endocrinology.

[48]  Z. Cohen,et al.  Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. , 1999, The American journal of pathology.

[49]  C. Chi,et al.  Abnormal transcripts of FHIT gene in thyroid cancer. , 1998, Oncology reports.

[50]  K. Pavelić,et al.  Human tumour bank in Croatia: a possible model for a small bank as part of the future European tumour bank network. , 1994, European journal of cancer.

[51]  J. Fagin,et al.  High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. , 1993, The Journal of clinical investigation.

[52]  K. Kinzler,et al.  Oncogenic forms of p53 inhibit p53-regulated gene expression. , 1992, Science.